TARSUS PHARMACEUTICALS INC (TARS)
US87650L1035 - Common Stock
TARS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of TARS is average, but there are quite some concerns on its profitability. TARS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TARS had negative earnings in the past year.
In the past year TARS has reported a negative cash flow from operations.
TARS had negative earnings in each of the past 5 years.
TARS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TARS's Return On Assets of -35.70% is in line compared to the rest of the industry. TARS outperforms 47.89% of its industry peers.
The Return On Equity of TARS (-56.57%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.7% | ||
| ROE | -56.57% | ||
| ROIC | N/A |
ROA(3y)-28.72%
ROA(5y)-21.95%
ROE(3y)-36.49%
ROE(5y)-26.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 92.97%, TARS belongs to the top of the industry, outperforming 96.84% of the companies in the same industry.
TARS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
TARS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TARS has more shares outstanding
The debt/assets ratio for TARS is higher compared to a year ago.
2.2 Solvency
TARS has an Altman-Z score of 7.53. This indicates that TARS is financially healthy and has little risk of bankruptcy at the moment.
TARS has a Altman-Z score of 7.53. This is amongst the best in the industry. TARS outperforms 84.74% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that TARS is not too dependend on debt financing.
The Debt to Equity ratio of TARS (0.30) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.53 |
ROIC/WACCN/A
WACC9.86%
2.3 Liquidity
A Current Ratio of 5.42 indicates that TARS has no problem at all paying its short term obligations.
The Current ratio of TARS (5.42) is better than 68.42% of its industry peers.
TARS has a Quick Ratio of 5.38. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TARS (5.38) is better than 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.42 | ||
| Quick Ratio | 5.38 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.26% over the past year.
TARS shows a strong growth in Revenue. In the last year, the Revenue has grown by 802.03%.
EPS 1Y (TTM)0.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.34%
Revenue 1Y (TTM)802.03%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2471.78%
3.2 Future
Based on estimates for the next years, TARS will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.25% on average per year.
TARS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 142.78% yearly.
EPS Next Y28.74%
EPS Next 2Y26.6%
EPS Next 3Y34.26%
EPS Next 5Y19.25%
Revenue Next Year1660.68%
Revenue Next 2Y458.2%
Revenue Next 3Y269.38%
Revenue Next 5Y142.79%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TARS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TARS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TARS's earnings are expected to grow with 34.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.6%
EPS Next 3Y34.26%
5. Dividend
5.1 Amount
TARS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TARSUS PHARMACEUTICALS INC
NASDAQ:TARS (12/23/2024, 11:26:56 AM)
53.67
+0.76 (+1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners100.18%
Inst Owner Change7.83%
Ins Owners3.47%
Ins Owner Change0.52%
Market Cap2.05B
Analysts86.67
Price Target66.3 (23.53%)
Short Float %22.62%
Short Ratio9.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.56%
Min EPS beat(2)6.62%
Max EPS beat(2)38.51%
EPS beat(4)4
Avg EPS beat(4)17.17%
Min EPS beat(4)5.75%
Max EPS beat(4)38.51%
EPS beat(8)7
Avg EPS beat(8)13.69%
EPS beat(12)10
Avg EPS beat(12)15.28%
EPS beat(16)12
Avg EPS beat(16)28.16%
Revenue beat(2)2
Avg Revenue beat(2)17.49%
Min Revenue beat(2)8.6%
Max Revenue beat(2)26.37%
Revenue beat(4)4
Avg Revenue beat(4)54.09%
Min Revenue beat(4)8.6%
Max Revenue beat(4)126.31%
Revenue beat(8)5
Avg Revenue beat(8)56.45%
Revenue beat(12)6
Avg Revenue beat(12)16.37%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.11%
EPS NQ rev (1m)-2.59%
EPS NQ rev (3m)11.89%
EPS NY rev (1m)14.63%
EPS NY rev (3m)14.18%
Revenue NQ rev (1m)5.76%
Revenue NQ rev (3m)26.51%
Revenue NY rev (1m)6.59%
Revenue NY rev (3m)7.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 15.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.64 | ||
| P/tB | 8.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.81
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.62
OCFYN/A
SpS3.39
BVpS6.21
TBVpS5.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.7% | ||
| ROE | -56.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.97% | ||
| FCFM | N/A |
ROA(3y)-28.72%
ROA(5y)-21.95%
ROE(3y)-36.49%
ROE(5y)-26.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 131.32% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.42 | ||
| Quick Ratio | 5.38 | ||
| Altman-Z | 7.53 |
F-Score3
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)376.45%
Cap/Sales(3y)11.52%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.34%
EPS Next Y28.74%
EPS Next 2Y26.6%
EPS Next 3Y34.26%
EPS Next 5Y19.25%
Revenue 1Y (TTM)802.03%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2471.78%
Revenue Next Year1660.68%
Revenue Next 2Y458.2%
Revenue Next 3Y269.38%
Revenue Next 5Y142.79%
EBIT growth 1Y-23.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.44%
EBIT Next 3Y31.58%
EBIT Next 5Y21.31%
FCF growth 1Y-99.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.24%
OCF growth 3YN/A
OCF growth 5YN/A